Dr. Eldridge began an interesting thread this past week regarding ocular surface disease in glaucoma patients. He reminded us that dry eye disease can often be silent in patients after chronic administration of BAK preservatives have reduced corneal … [Read more...]
Chronic BAK exposure is associated with an increase in tear osmolarity
Breakthrough in Diagnosing Dry Eye and Staging Disease Severity
In January's edition of Cataract and Refractive Surgery Today, Jay Pepose, MD, PhD says.... A lot depends on treating patients with dry eye disease. Nearly one in five individuals in North America has dry eye disease (DED); it may be one of the most common yet frequently undiagnosed and untreated problems seen every day by … [Read more...]
TearLab Osmolarity System CLIA Waiver Issued By FDA
SAN DIEGO, January 24, 2012 -- TearLab Corporation (NASDAQ:TEAR; TSX:TLB) ("TearLab" or the "Company") announced today that, after reviewing and accepting labeling submitted to it by the Company, the U.S Food and Drug Administration (“FDA”) has now granted Waiver categorization under the Clinical Laboratory Improvement … [Read more...]
Recent study shows preservative-free tafluprost offers effective treatment with less ocular surface impact for glaucoma patients
We have known for years BAK is often a cause for ocular discomfort for patients. "Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma" in Clinical Ophthalmology Jan 2012 looks at tear osmolarity, corneal staining and OSDI in … [Read more...]
ESTABLISHING A DRY EYE SUBSPECIALTY CLINIC

See this weeks Practice Pearl from Paul Karpecki, OD where he discusses the many diagnostic instruments he would like to include in his "dream dry eye practice". He mentions the TearLab Osmolarity System, among others. http://www.revoptom.com/email/010912_pearl86_v2.html … [Read more...]
The Advent of Tear Osmolarity

The advent of tear osmolarity as a practical tool for diagnosis, determination of severity of disease and as a reliable objective measure of response to treatment is a game changer for clinicians faced daily in their offices with patients suffering from this disease. TearLab Corporation recently received a letter from the FDA … [Read more...]
TearLab Achieves Equal Reimbursement Across All States
December has turned out to be quite a month for TearLab Corporation. TearLab achieved their largest milestone last week when they received FDA communication granting them the CLIA waiver for the TearLab® Osmolarity System (pending labeling agreements). In addition, in a press release on Tuesday of this week, TearLab announced … [Read more...]
TearLab Published in AAO Preferred Practice Patterns

The American Academy of Ophthalmology in September published a partial revision of the Preferred Practice Patterns for Dry Eye. In this, tear osmolarity was added to the recommended diagnostic tests for dry eye disease and specifically the TearLab was referenced. This recognition by the Academy’s panel of the critical role tear … [Read more...]
In My Practice : Marguerite B. McDonald, MD, FACS

Dr. McDonald is the Cornea/refractive/anterior segment specialist, Ophthalmic Consultants of Long Island, Lynbrook, NY. She is presently an Adjunct Clinical Professor of Ophthalmology at Tulane University School of Medicine in New Orleans and a Clinical Professor of Ophthalmology at New York University (NYU) in Manhattan. Dr … [Read more...]
TearLab continues to gain acceptance amongst thought leaders

TearLab’s (NASDAQ:TEAR; TSX:TLB) osmolarity test for dry eye disease continues to make impressive inroads in gaining awareness and acceptance among U.S. eye doctors. TearLab Osmolarity Test For example, an article entitled “Tear Osmolarity in the Diagnosis and Management of Dry Eye Disease,” which appeared in the … [Read more...]




